Bio­gen climbs high­er on Spin­raza sales; inks deal for two new neu­ro­mus­cu­lar drugs

Bio­gen is climb­ing on the Nas­daq Tues­day morn­ing fol­low­ing news that it’s ac­quired two ear­ly-stage drugs for neu­ro­mus­cu­lar dis­or­ders, adding to the com­pa­ny’s pipeline of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER